Abstract:Highlights • Intracellular ROS kinetics dictates antigen-presenting mode. • Sustained TLR2 activation triggers intracellular ROS kinetics required for cross-presentation. • A scaffold vaccine enabling "retention-and-release" for sustained TLR2 activation in DCs promotes cross-presentation. • The scaffold vaccine induces robust, CD8 + T cells-mediated anti-tumor immune responses in Apc min/+ transgenic mice. Cancer vaccination holds great promise for cancer treatment, but its effectiveness is hindered by suboptimal activation of CD8 + cytotoxic T lymphocytes, which are potent effectors to mediate anti-tumor immune responses. A possible solution is to switch antigen-presenting cells to present tumor antigens via the major histocompatibility complex class I (MHC-I) to CD8 + T cells – a process known as cross-presentation. To achieve this goal, we develop a three-dimensional (3D) scaffold vaccine to promote antigen cross-presentation by persisted toll-like receptor-2 (TLR2) activation after one injection. This vaccine comprises polysaccharide frameworks that "hook" TLR2 agonist (acGM) via tunable hydrophobic interactions and forms a 3D macroporous scaffold via click chemistry upon subcutaneous injection. Its retention-and-release of acGM enables sustained TLR2 activation in abundantly recruited dendritic cells in situ , inducing intracellular production of reactive oxygen species (ROS) in optimal kinetics that crucially promotes efficient antigen cross-presentation. The scaffold loaded with model antigen ovalbumin (OVA) or tumor specific antigen can generate potent immune responses against lung metastasis in B16-OVA-innoculated wild-type mice or spontaneous colorectal cancer in transgenic Apc Min/+ mice, respectively. Notably, it requires neither additional adjuvants nor external stimulation to function and can be adjusted to accommodate different antigens. The developed scaffold vaccine may represent a new, competent tool for next-generation personalized cancer vaccination. Graphical abstract A scaffold vaccine that promotes antigen cross-presentation to trigger CD8 + T cell-mediated anti-tumor immune responses . In this study, we discover that the kinetics of intracellular ROS, unexpectedly, dictates the mode of antigen presentation. Persistent production in moderate dose promotes antigen cross-presentation. To create optimal intracellular ROS kinetics for lysosomal disruption and antigen escape, we design a 3D injectable scaffold for the "retention-and-release" of a TLR2 agonist glycan upon subcutaneous implantation. Installation of tunable hydrophobic interactions between the scaffold and the "hooked" agonist enables sustained TLR activation in the abundantly recruited DCs in situ , which triggers consequently efficient cross-presentation of tumor antigens. The efficacy of this novel scaffold vaccine is subsequently undergoing comprehensive evaluations in both wild-type and transgenic mice against localized, metastatic, and spontaneous tumors. Download : Download high-res image (369KB) Download : Download full-size image

Blood Clot Scaffold Loaded with Liposome Vaccine and siRNAs Targeting PD-L1 and TIM-3 for Effective DC Activation and Cancer Immunotherapy

Engineering ROS‐Responsive Bioscaffolds for Disrupting Myeloid Cell‐Driven Immunosuppressive Niche to Enhance PD‐L1 Blockade‐Based Postablative Immunotherapy

A Dual Enhancing Strategy of Novel Nanovaccine Based on TIM3 Silencing Nanoadjuvants and Desialylated Cancer Cell Membrane Antigens for Personalized Vaccination Immunotherapy of Cancer

Programing Immunogenic Cell Death in Breast Tumors with Designer DNA Frameworks

Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.

Amplified cancer immunotherapy of PD-L1 blockade by sequential tumor microenvironment reshaping and DC maturation

Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy

A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy

Bionic Immunoactivator Copresenting Autophagy Promoting and Costimulatory Molecules for Synergistic Cancer Immunotherapy

Lymph-targeted high-density lipoprotein-mimetic nanovaccine for multi-antigenic personalized cancer immunotherapy

Uplifting Antitumor Immunotherapy with Lymph-Node-Targeted and Ratio-Controlled Codelivery of Tumor Cell Lysate and Adjuvant

CD47KO/CRT Dual-Bioengineered Cell Membrane-Coated Nanovaccine Combined with Anti-Pd-l1 Antibody for Boosting Tumor Immunotherapy.

Exploiting Immunostimulatory Mechanisms of Immunogenic Cell Death to Develop Membrane-Encapsulated Nanoparticles As a Potent Tumor Vaccine.

Eliciting Immunogenic Cell Death Via Tumor-Associated Fibroblast Inactivation and Autophagy Induction with Doxorubicin and Silybin Loaded Molecularly Imprinted Nanosystem

Dual-responsive PEG-lipid Polyester Nanoparticles for Sirna and Vaccine Delivery Elicit Anti-Cancer Immune Responses by Modulating Tumor Microenvironment

A scaffold vaccine to promote tumor antigen cross-presentation via sustained toll-like receptor-2 (TLR2) activation

Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy

Self-assembled immunostimulatory nanosphere combined with PD-L1 to enhanced cancer chemoimmunotherapy

Redox-responsive Nanoassembly Restrained Myeloid-Derived Suppressor Cells Recruitment Through Autophagy-Involved Lactate Dehydrogenase A Silencing for Enhanced Cancer Immunochemotherapy.

Split Bullets Loaded Nanoparticles for Amplified Immunotherapy

LncRNA-edited biomimetic nanovaccines combined with anti-TIM-3 for augmented immune checkpoint blockade immunotherapy